NHC Key Laboratory of Drug Addiction Medicine, Division of Epidemiology and Health Statistics, School of Public Health, Kunming Medical University, Chengong District, 1168 West Chunrong Road, Yuhua Street, Kunming, Yunnan, China.
BMC Cancer. 2023 Dec 18;23(1):1248. doi: 10.1186/s12885-023-11738-w.
Existing literature suggests that tertiary lymphatic structure (TLS) is associated with the progression of cancer. However, the prognostic role of TLS in digestive system cancers remains controversial. This meta-analysis aims to synthesize currently available evidence in the association between TLS and the survival of digestive system cancers.
We systematically searched three digital databases (PubMed, Embase, Web of Science) for articles published from database inception to December 23, 2022. Study selection criteria are based on PECO framework: P (population: patients with digestive system cancers), E (exposure: presence of TLS), C (comparator: absence of TLS), O (outcome: overall survival, OS; recurrence-free survival, RFS; disease-free survival, DFS). The Quality in Prognostic Studies (QUIPS) tool was used to assess risk of bias for included studies. The study protocol was registered with PROSPERO (CRD42023416307).
A total of 25 studies with 6910 patients were included into the final meta-analysis. Random-effects models revealed that the absence of TLS was associated with compromised OS, RFS, and DFS of digestive system cancers, with pooled hazard ratios (HRs) of 1.74 (95% CI: 1.50-2.03), 1.96 (95% CI: 1.58-2.44), and 1.81 (95% CI: 1.49-2.19), respectively. Subgroup analyses disclosed a stronger TLS-survival association for pancreatic cancer, compared with other digestive system cancers.
TLS may be of prognostic significance for digestive system cancers. More original studies are needed to further corroborate this finding.
现有文献表明,三级淋巴结构(TLS)与癌症的进展有关。然而,TLS 与消化系统癌症患者生存的相关性的预后作用仍存在争议。本荟萃分析旨在综合目前关于 TLS 与消化系统癌症患者生存之间相关性的可用证据。
我们系统地检索了三个数字数据库(PubMed、Embase、Web of Science),检索时间从数据库建立到 2022 年 12 月 23 日。研究选择标准基于 PECO 框架:P(人群:患有消化系统癌症的患者)、E(暴露:存在 TLS)、C(对照组:不存在 TLS)、O(结局:总生存 OS;无复发生存 RFS;无疾病生存 DFS)。使用预后研究质量工具(QUIPS)评估纳入研究的偏倚风险。研究方案已在 PROSPERO(CRD42023416307)上注册。
共有 25 项研究纳入了 6910 例患者,最终纳入荟萃分析。随机效应模型显示,TLS 缺失与消化系统癌症的 OS、RFS 和 DFS 受损相关,合并风险比(HR)分别为 1.74(95%CI:1.50-2.03)、1.96(95%CI:1.58-2.44)和 1.81(95%CI:1.49-2.19)。亚组分析显示,与其他消化系统癌症相比,TLS 与胰腺癌的生存相关性更强。
TLS 可能对消化系统癌症具有预后意义。需要更多的原始研究来进一步证实这一发现。